JP2011527894A - Per.c6細胞の培養およびそれからの生成物の生産のための拡張可能なプロセス - Google Patents
Per.c6細胞の培養およびそれからの生成物の生産のための拡張可能なプロセス Download PDFInfo
- Publication number
- JP2011527894A JP2011527894A JP2011517878A JP2011517878A JP2011527894A JP 2011527894 A JP2011527894 A JP 2011527894A JP 2011517878 A JP2011517878 A JP 2011517878A JP 2011517878 A JP2011517878 A JP 2011517878A JP 2011527894 A JP2011527894 A JP 2011527894A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- per
- microcarriers
- culture
- positively charged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012258 culturing Methods 0.000 title claims abstract description 10
- 238000010963 scalable process Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 36
- 229920002307 Dextran Polymers 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 abstract description 4
- 230000001070 adhesive effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 115
- 238000004519 manufacturing process Methods 0.000 description 23
- 239000000047 product Substances 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 19
- 230000001464 adherent effect Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 12
- 239000000969 carrier Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 238000013341 scale-up Methods 0.000 description 8
- 238000004114 suspension culture Methods 0.000 description 6
- 108010014172 Factor V Proteins 0.000 description 5
- 238000004115 adherent culture Methods 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010074864 Factor XI Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241000282465 Canis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
- C12N5/0075—General culture methods using substrates using microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/20—Small organic molecules
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本発明の概略
例2:普通に用いられるマイクロキャリア上のPER.C6細胞の培養
例3:正荷電マイクロキャリア上のPER.C6細胞の成功した培養
例4:スピナーにおける正荷電担体上のPER.C6細胞のバッチ培養
例5:バイオリアクターにおける正荷電担体上のPER.C6細胞のバッチ培養
例6:正荷電担体上のPER.C6細胞による組換えタンパク質の生産
例7:期待されるプロセス
(1)Brands et al. Influvac: A safe madin darby canine kidney (MDCK) cell culture-based influenza vaccine in Brown F, Robertson JS, Schild GC, Wood JM: Inactivated influenza vaccines prepared in cell culture, Dev Biol Stand. Basel, Karger, 1999, vol 98, pp 93-100.
(2)Bruhl P, Kerschbaum A, Kistner O, Barrett N, Dorner F, Gerencer M. Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine. Vaccine 19 (2001) 1149-1158.
(3)Chu L, and Robinson, D. Industrial choices for protein production by large-scale cell culture. Current Opinion in Biotechnology 2001, 12: 180-187.
(4)Griffiths B. Scale-up of suspension and anchorage-dependent animal cells. Molecular Biotechnology, Volume 17, 2001.
(5)Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, van der Helm E, Smits S, Schouten J, Brouwer K, Lagerwerf F, van Berkel P, Opstelten DJ, Logtenberg T, Bout A. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol Prog. 2003 Jan-Feb;19(1):163-8.
(6)Kong D, Chen M, Gentz R & Zhang J. Cell growth and protein formation on various microcarriers. Cytotechnology 29: 149-156, 1999.
(7)Rourou S, Van der Ark A, Van der Velden T, Kallel H. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine 25 (2007) 3879-3889.
(8)Yallop C, Crowley J, Cote J, Hegmans-Brouwer K, Lagerwerf F, Gagne R, Martin JC, Oosterhuis N, Opstelten DJ, Bout A. Per.C6 cells for the manufacture of biopharmaceutical proteins. Modern Biopharmaceuticals - Design, Development and Optimization. Vol. 3, 2005.
Claims (10)
- a)PER.C6細胞を正に荷電されたマイクロキャリアに付着させること、および
b)前記細胞を培地において培養すること
を含む、PER.C6細胞を接着させて培養するための方法。 - さらに、c)前記細胞をマイクロキャリアから分離し、そして次いで前記細胞をさらに培養すること
のステップを含む、請求項1に記載の方法。 - 正荷電マイクロキャリアはN,N,−ジエチルアミノエチル基を含む、先行する請求項のいずれか一項に記載の方法。
- 前記マイクロキャリアはデキストラン系である、先行する請求項のいずれか一項に記載の方法。
- 前記細胞は生成物を生産する、先行する請求項のいずれか一項に記載の方法。
- 前記生成物はタンパク質である、請求項5に記載の方法。
- 前記生成物は血液凝固因子である、請求項5に記載の方法。
- さらに、d)前記産物を収集すること
のステップを含む、請求項5、6および7のいずれか一項に記載の方法。 - マイクロキャリアに付着したPER.C6細胞を含み、前記マイクロキャリアが正に荷電されている、培養物。
- 前記正荷電マイクロキャリアはN,N,−ジエチルアミノエチル基を含む、請求項9に記載の培養物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13499208P | 2008-07-15 | 2008-07-15 | |
US61/134,992 | 2008-07-15 | ||
EP08160392 | 2008-07-15 | ||
EP08160392.0 | 2008-07-15 | ||
PCT/EP2009/058761 WO2010006989A1 (en) | 2008-07-15 | 2009-07-09 | Scalable process for culturing per.c6 cells and producing products therefrom |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011527894A true JP2011527894A (ja) | 2011-11-10 |
JP5684122B2 JP5684122B2 (ja) | 2015-03-11 |
Family
ID=40219360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011517878A Active JP5684122B2 (ja) | 2008-07-15 | 2009-07-09 | Per.c6細胞の培養およびそれからの生成物の生産のための拡張可能なプロセス |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110159543A1 (ja) |
EP (1) | EP2307538B1 (ja) |
JP (1) | JP5684122B2 (ja) |
KR (1) | KR101639454B1 (ja) |
CN (1) | CN102216449B (ja) |
AU (1) | AU2009272857B2 (ja) |
CA (1) | CA2728477C (ja) |
DK (1) | DK2307538T3 (ja) |
ES (1) | ES2558436T3 (ja) |
PL (1) | PL2307538T3 (ja) |
WO (1) | WO2010006989A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014019990A1 (en) | 2012-08-03 | 2014-02-06 | Sanofi Pasteur | Production of infectious influenza viruses |
TWI480989B (zh) | 2012-10-02 | 2015-04-11 | 矽品精密工業股份有限公司 | 半導體封裝件及其製法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063403A2 (en) * | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
WO2001038362A2 (en) * | 1999-11-26 | 2001-05-31 | Crucell Holland B.V. | Production of vaccines |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415668A (en) * | 1981-04-20 | 1983-11-15 | President And Fellows Of Harvard College | Cell culture |
US5661008A (en) * | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
US5512474A (en) * | 1992-05-29 | 1996-04-30 | Bsi Corporation | Cell culture support containing a cell adhesion factor and a positively-charged molecule |
SI0833934T2 (sl) * | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
HUP0402158A2 (hu) * | 2001-10-02 | 2005-01-28 | Novo Nordisk Health Care Ag | Rekombináns fehérjék előállítási eljárása eukarióta sejtekben |
EP2102335B1 (en) * | 2007-01-04 | 2012-02-22 | Crucell Holland B.V. | Purification of factor xi |
-
2009
- 2009-07-09 PL PL09797474T patent/PL2307538T3/pl unknown
- 2009-07-09 ES ES09797474.5T patent/ES2558436T3/es active Active
- 2009-07-09 JP JP2011517878A patent/JP5684122B2/ja active Active
- 2009-07-09 KR KR1020107026981A patent/KR101639454B1/ko active IP Right Grant
- 2009-07-09 CN CN2009801241445A patent/CN102216449B/zh active Active
- 2009-07-09 DK DK09797474.5T patent/DK2307538T3/da active
- 2009-07-09 US US12/736,997 patent/US20110159543A1/en not_active Abandoned
- 2009-07-09 AU AU2009272857A patent/AU2009272857B2/en not_active Ceased
- 2009-07-09 CA CA2728477A patent/CA2728477C/en active Active
- 2009-07-09 WO PCT/EP2009/058761 patent/WO2010006989A1/en active Application Filing
- 2009-07-09 EP EP09797474.5A patent/EP2307538B1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063403A2 (en) * | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
WO2001038362A2 (en) * | 1999-11-26 | 2001-05-31 | Crucell Holland B.V. | Production of vaccines |
Non-Patent Citations (3)
Title |
---|
JPN6013064078; SUBRAMANIAN,S. et al.: 'Scaleable production of adenoviral vectors by transfection of adherent PER.C6 cells.' Biotechnol. Prog. Vol.23, No.5, 200709, pp.1210-7 * |
JPN6013064080; PADILLA,J. et al.: 'Pretreatment with polycations enhances adenoviral infection levels in serum-free PER.C6 cells as wel' Animal Cell Technology Meets Genomics , 2005, pp.281-3 * |
JPN6013064082; JONES,D. et al.: 'High-level expression of recombinant IgG in the human cell line per.c6.' Biotechnol. Prog. Vol.19, No.1, 200301, pp.163-8 * |
Also Published As
Publication number | Publication date |
---|---|
DK2307538T3 (da) | 2016-01-18 |
AU2009272857A1 (en) | 2010-01-21 |
CN102216449B (zh) | 2013-03-06 |
CN102216449A (zh) | 2011-10-12 |
EP2307538A1 (en) | 2011-04-13 |
ES2558436T3 (es) | 2016-02-04 |
CA2728477A1 (en) | 2010-01-21 |
WO2010006989A1 (en) | 2010-01-21 |
EP2307538B1 (en) | 2015-10-21 |
JP5684122B2 (ja) | 2015-03-11 |
CA2728477C (en) | 2017-02-28 |
KR20110041435A (ko) | 2011-04-21 |
US20110159543A1 (en) | 2011-06-30 |
KR101639454B1 (ko) | 2016-07-13 |
AU2009272857B2 (en) | 2015-06-18 |
PL2307538T3 (pl) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Derakhti et al. | Attachment and detachment strategies in microcarrier-based cell culture technology: A comprehensive review | |
Merten | Advances in cell culture: anchorage dependence | |
Reuveny | Microcarrier culture systems | |
US20080009064A1 (en) | Temperature-Responsive Microcarrier | |
US6214618B1 (en) | Microcarrier beads having a styrene copolymer core and a covalently linked tri-methylamine exterior | |
Nilsson | Microcarrier cell culture | |
JP5096920B2 (ja) | ウイルス物質の製造方法 | |
JP4650798B2 (ja) | ウイルスの生産方法 | |
JP4723862B2 (ja) | 細胞培養支持体を被覆する方法 | |
JP2024071406A (ja) | ベロ細胞培養用低血清培地組成物およびその利用 | |
JP2006511219A6 (ja) | 細胞培養支持体を被覆する方法 | |
Li et al. | Preparation of microcarriers based on zein and their application in cell culture | |
JP5684122B2 (ja) | Per.c6細胞の培養およびそれからの生成物の生産のための拡張可能なプロセス | |
AU2009243226B2 (en) | Product for cell culture | |
JP2018533374A (ja) | ワクチン生産のための無血清合成培地中のmdck浮遊細胞株 | |
Duffy et al. | A concept for continuous virus manufacture using a moving bed bioreactor: Growth of MDCK cells to confluence on paper as a model support | |
JP2017136042A (ja) | 多孔性マイクロキャリアを用いた細胞培養方法 | |
WO2023025812A1 (en) | Methods for production of engineered cells | |
WO2024134183A1 (en) | Culture methods | |
Ayhan et al. | Attachment of 3T3 and MDBK cells onto PHEMA-based microbeads and their biologically modified forms | |
Ayhan et al. | Cell growth on poly (EGDMA/HEMA) based microbeads | |
Kumar et al. | Recent advances in meat production–a review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120703 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141128 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5684122 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |